Targeted radiotherapy for high-risk neuroblastoma
Research Project 2: Neuroblastoma
This project looks at how the targeted radioactive drug 131I-MIBG affects tumors and long-term health in children with high-risk neuroblastoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11178332 on NIH RePORTER |
What this research studies
If my child is part of this project, researchers will study tumor samples, imaging, and blood from children treated with the targeted radiopharmaceutical 131I-MIBG. They will examine tumor-intrinsic features and the surrounding cells using gene sequencing, single-cell and bulk RNA tests, and DNA damage repair profiling before treatment to understand the starting biology. They will follow how tumors and blood markers change after 131I-MIBG, including analysis of tissue removed after treatment and serial circulating tumor DNA samples. The team will also use data from two large national studies to look for late effects and other longer-term outcomes in children who received 131I-MIBG.
Who could benefit from this research
Good fit: Children with high-risk neuroblastoma who are receiving or being considered for 131I-MIBG therapy are the ideal candidates.
Not a fit: Children without neuroblastoma or those not treated with 131I-MIBG would not be eligible and are unlikely to benefit directly.
Why it matters
Potential benefit: Could help doctors tailor radiopharmaceutical treatment and identify children at higher risk for long-term side effects.
How similar studies have performed: Targeted radiopharmaceuticals like 131I-MIBG have demonstrated clinical benefit in neuroblastoma, but deep molecular and tumor-microenvironment studies of response and late effects are relatively new.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Chowdhury, Dipanjan — Dana-Farber Cancer Inst
- Study coordinator: Chowdhury, Dipanjan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.